Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Common Equity: 2010-2021

Historic Common Equity for Neurocrine Biosciences (NBIX) over the last 11 years, with Sep 2021 value amounting to $1.3 billion.

  • Neurocrine Biosciences' Common Equity rose 67.35% to $1.3 billion in Q3 2021 from the same period last year, while for Sep 2021 it was $1.3 billion, marking a year-over-year increase of 67.35%. This contributed to the annual value of $1.1 billion for FY2020, which is 76.83% up from last year.
  • According to the latest figures from Q3 2021, Neurocrine Biosciences' Common Equity is $1.3 billion, which was up 5.22% from $1.3 billion recorded in Q2 2021.
  • Neurocrine Biosciences' 5-year Common Equity high stood at $1.3 billion for Q3 2021, and its period low was $247.1 million during Q1 2017.
  • In the last 3 years, Neurocrine Biosciences' Common Equity had a median value of $804.3 million in 2020 and averaged $854.3 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' Common Equity crashed by 40.15% in 2017, and later spiked by 76.83% in 2020.
  • Neurocrine Biosciences' Common Equity (Quarterly) stood at $372.1 million in 2017, then rose by 29.19% to $480.8 million in 2018, then spiked by 32.48% to $636.9 million in 2019, then soared by 76.83% to $1.1 billion in 2020, then skyrocketed by 67.35% to $1.3 billion in 2021.
  • Its Common Equity stands at $1.3 billion for Q3 2021, versus $1.3 billion for Q2 2021 and $1.2 billion for Q1 2021.